In the years following publication of the DSM-5(R), the field of psychiatry has seen vigorous debate between the DSM's more traditional, diagnosis-oriented approach and the NIMH's more biological, dimension-based RDoC (research domain criteria) approach. Charney & Nestler's Neurobiology of Mental Illness is an authoritative foundation for translating information from the laboratory to clinical treatment, and its fifth edition extends beyond this reference function to acknowledge and examine the controversies, different camps, and thoughts on the future of psychiatric diagnosis. In this wider context, this book provides information from numerous levels of analysis, including molecular biology and genetics, cellular physiology, neuroanatomy, neuropharmacology, epidemiology, and behavior. Sections and chapters are edited and authored by experts at the top of their fields. No other book distills the basic science and underpinnings of mental disorders-and highlights practical clinical significance-to the scope and breadth of this classic text. In this edition, Section 1, which reviews the methods used to examine the biological basis of mental illness in animal and cell models and in humans, has been expanded to reflect critically important technical advances in complex genetics (including powerful sequencing technologies and related bioinformatics), epigenetics, stem cell biology, optogenetics, neural circuit functioning, cognitive neuroscience, and brain imaging. This range of established and emerging methodologies offer groundbreaking advances in our ability to study the brain as well as unique opportunities for the translation of preclinical and clinical research into badly needed breakthroughs in our therapeutic toolkit. Sections 2 through 7 cover the neurobiology and genetics of major psychiatric disorders: psychoses (including bipolar disorder), mood disorders, anxiety disorders, substance use disorders, dementias, and disorders of childhood onset. Also covered within these sections is a summary of current therapeutic approaches for these illnesses as well as the ways in which research advances are now guiding the search for new treatments. Each of these parts has been augmented in several different areas as a reflection of research progress. The last section, Section 8, reconfigured in this new edition, now focuses on diagnostic schemes for mental illness. This includes an overview of the unique challenges that remain in diagnosing these disorders given our still limited knowledge of disease etiology and pathophysiology. The section then provides reviews of DSM-5(R), which forms the basis of psychiatric diagnosis in the United States for all clinical work, and of RDoC, which provides an alternative perspective on diagnosis in heavy use in the research community. Also included are chapters on future efforts toward precision and computational psychiatry, which promise to someday align diagnosis with underlying biological abnormalities.

Our understanding of the neurobiological basis of psychiatric disease has accelerated in the past five years. The fourth edition of Neurobiology of Mental Illness has been completely revamped given these advances and discoveries on the neurobiologic foundations of psychiatry. Like its predecessors the book begins with an overview of the basic science. The emerging technologies in Section 2 have been extensively redone to match the progress in the field including new chapters on the applications of stem cells, optogenetics, and image guided stimulation to our understanding and treatment of psychiatric disorders. Sections' 3 through 8 pertain to the major psychiatric syndromes-the psychoses, mood disorders, anxiety disorders, substance use disorders, dementias, and disorders of childhood-onset. Each of these sections includes our knowledge of their etiology, pathophysiology, and treatment. The final section discusses special topic areas including the neurobiology of sleep, resilience, social attachment, aggression, personality disorders and eating disorders. In all, there are 32 new chapters in this volume including unique insights on DSM-5, the Research Domain Criteria (RDoC) from NIMH, and a perspective on the continuing challenges of diagnosis given what we know of the brain and the mechanisms pertaining to mental illness. This book provides information from numerous levels of analysis including molecular biology and genetics, cellular physiology, neuroanatomy, neuropharmacology, epidemiology, and behavior. In doing so it translates information from the basic laboratory to the clinical laboratory and finally to clinical treatment. No other book distills the basic science and underpinnings of mental disorders and explains the clinical significance to the scope and breadth of this classic text. The result is an excellent and cutting-edge resource for psychiatric residents, psychiatric researchers and doctoral students in neurochemistry and the neurosciences.

This is a new edition of the first comprehensive text to show how the advances in molecular and cellular biology and in the basic neurosciences have brought the revolution in molecular medicine to the field of psychiatry. The book begins with a review of basic neuroscience and methods for studying neurobiology in human patients then proceeds to discussions of all major psychiatric syndromes with respect to knowledge of their etiology, pathophysiology, and treatment. Emphasis is placed on synthesizing information across numerous levels of analysis, including molecular biology and genetics, cellular physiology, neuroanatomy, neuropharmacology, and behavior, and in translating information from the basic laboratory to the clinical laboratory and finally to clinical treatment. Editors Dennis Charney and Eric Nestle, along with their six section editors and over 150 contributors, have revised and updated all 80 chapters from the previous edition and have added new chapters on topics relating to, for example, genetics, experimental therapeutics, and late-life mood disorders. Both a textbook and a reference book, Neurobiology of Mental Illness is intended for psychiatrists, neuroscientists, and upper level students.

Thoroughly updated and completely reorganized for a sharper clinical focus, the Fifth Edition of this world-renowned classic synthesizes the latest advances in basic neurobiology, biological psychiatry, and clinical neuropsychopharmacology. The book establishes a critical bridge connecting new discoveries in molecular and cellular biology, genetics, and neuroimaging with the etiology, diagnosis, and treatment of all neuropsychiatric disorders. Nine sections focus on specific groups of disorders, covering clinical course, genetics, neurobiology, neuroimaging, and current and emerging therapeutics. Four sections cover neurotransmitter and signal transduction, emerging methods in molecular biology and genetics, emerging imaging technologies and their psychiatric applications, and drug discovery and evaluation. Compatibility: BlackBerry(R) OS 4.1 or Higher / iPhone/iPod Touch 2.0 or Higher /Palm OS 3.5 or higher / Palm Pre Classic / Symbian S60, 3rd edition (Nokia) / Windows Mobile(TM) Pocket PC (all versions) / Windows Mobile Smartphone / Windows 98SE/2000/ME/XP/Vista/Tablet PC

Research has shown that a range of adult psychiatric disorders and mental health problems originate at an early age, yet the psychiatric symptoms of an increasing number of children and adolescents are going unrecognized and untreated—there are simply not enough child psychiatric providers to meet this steadily rising demand. It is vital that advanced practice registered nurses (APRNs) and primary care practitioners take active roles in assessing behavioral health presentations and work collaboratively with families and other healthcare professionals to ensure that all children and adolescents receive appropriate treatment. Child and Adolescent Behavioral Health helps APRNs address the mental health needs of this vulnerable population, providing practical guidance on assessment guidelines, intervention and treatment strategies, indications for consultation, collaboration, referral, and more. Now in its second edition, this comprehensive and timely resource has been fully updated to include DSM-5 criteria and the latest guidance on assessing, diagnosing, and treating the most common behavioral health issues facing young people. New and expanded chapters cover topics including eating disorders, bullying and victimization, LGBTQ identity issues, and conducting research with high-risk children and adolescents. Edited and written by a team of accomplished child psychiatric and primary care practitioners, this authoritative volume: Provides state-of-the-art knowledge about specific psychiatric and behavioral health issues in multiple care settings Reviews the clinical manifestation and etiology of behavioral disorders, risk and management issues, and implications for practice, research, and education Offers approaches for interviewing children and adolescents, and strategies for integrating physical and psychiatric screening Discusses special topics such as legal and ethical issues, cultural influences, the needs of immigrant children, and child and adolescent mental health policy Features a new companion website containing clinical case studies to apply concepts from the chapters Designed to specifically address the issues faced by APRNs, Child and Adolescent Behavioral Health is essential reading for nurse practitioners and clinical nurse specialists, particularly those working in family, pediatric, community health, psychiatric, and mental health settings. *Second Place in the Child Health Category, 2021 American Journal of Nursing Book of the Year Awards*

The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism.